Diana Harshbarger (R-TN)
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
A Republican bill with 18 Republican cosponsors · See all 18 cosponsors
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill seeks to nullify the changes made by the Food and Drug Administration in January 2023 regarding the risk evaluation and mitigation strategy for mifepristone. It specifically targets the modifications made to the strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act. Additionally, the bill prevents the Secretary of Health and Human Services from implementing any provisions that are substantially similar to those nullified modifications.
Yes
- Scored +3
Does this give the federal government more power?
The bill uses congressional authority to nullify specific regulatory actions taken by the FDA and HHS.
The opposite· 3 of 5
- Scored -7
Would women be better off under this?
The bill restricts reproductive options by nullifying the FDA's expanded access to mifepristone.
- Scored -7
Does this make abortion easier to get?
The bill nullifies FDA modifications to mifepristone distribution, which likely restricts access to the medication by reverting to more restrictive oversight.
- Scored -5
Does this narrow the gap between how men and women are treated?
By restricting the distribution of mifepristone, the bill potentially reduces women's autonomy over reproductive healthcare.
Who it would affect, and how
Potential Positive Impacts for People
- Restoration of Previous Regulations: By nullifying the January 2023 modifications, the bill would revert the risk evaluation and mitigation strategy for mifepristone to its prior state (Section 1(a)).
Potential Negative Impacts for People
- Prohibition of Similar Safety Strategies: The bill prevents the Secretary of Health and Human Services from establishing or enforcing any new provisions that are substantially similar to the nullified modifications (Section 1(b)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would women be better off under this? — The bill restricts reproductive options by nullifying the FDA's expanded access to mifepristone. Would households on low incomes be better off under this? — Restricting easier access to medication via mail or specific pharmacies can disproportionately burden low-income individuals who rely on such access. Would Hispanic Americans be better off under this? — The restriction of reproductive healthcare access can negatively impact disproportionately affected demographic groups.
- Healthcare
- Does this make abortion easier to get? — The bill nullifies FDA modifications to mifepristone distribution, which likely restricts access to the medication by reverting to more restrictive oversight.
- Social Issues And Justice
- Does this narrow the gap between how men and women are treated? — By restricting the distribution of mifepristone, the bill potentially reduces women's autonomy over reproductive healthcare.
- Governance And Ideology
- Does this give the federal government more power? — The bill uses congressional authority to nullify specific regulatory actions taken by the FDA and HHS.
- 2/4/2026
- 1 Cosponsor added.
- 3/31/2025
- 1 Cosponsor added.
- 2/4/2025
- 1 Cosponsor added.
- 1/28/2025
- 1 Cosponsor added.
- 1/23/2025
- Referred to the House Committee on Energy and Commerce.
- 14 Cosponsors added.
- Introduced in House
Brian BabinRepublican · Texas
Mike BostRepublican · Illinois
Andy BiggsRepublican · Arizona
James BairdRepublican · Indiana
Sheri BiggsRepublican · South Carolina
Randy FeenstraRepublican · Iowa
Michael GuestRepublican · Mississippi
Andy HarrisRepublican · Maryland
Clay HigginsRepublican · Louisiana
Kevin HernRepublican · Oklahoma
John MoolenaarRepublican · Michigan
Mary MillerRepublican · Illinois
Mark MessmerRepublican · Indiana
Gary PalmerRepublican · Alabama
Keith SelfRepublican · Texas
Daniel WebsterRepublican · Florida
Randy WeberRepublican · Texas
Rudy YakymRepublican · Indiana